These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23636219)

  • 61. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.
    Lambourne MD; Eltringham-Smith LJ; Gataiance S; Arnold DM; Crowther MA; Sheffield WP
    J Thromb Haemost; 2012 Sep; 10(9):1830-40. PubMed ID: 22817470
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model.
    Pragst I; Kaspereit F; Dörr B; Dickneite G
    Thromb Res; 2010 Mar; 125(3):272-7. PubMed ID: 19913880
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect.
    Nagakari K; Emmi M; Iba T
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):677-684. PubMed ID: 26984934
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
    Knight C; Danø AM; Kennedy-Martin T
    Haemophilia; 2009 Mar; 15(2):405-19. PubMed ID: 19187191
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
    Klintman J; Astermark J; Berntorp E
    Br J Haematol; 2010 Nov; 151(4):381-6. PubMed ID: 20977448
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model.
    Dickneite G; Dörr B; Kaspereit F; Tanaka KA
    J Trauma; 2010 May; 68(5):1151-7. PubMed ID: 19996804
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.
    Ogiwara K; Nogami K; Matsumoto T; Shima M
    Int J Hematol; 2014; 99(5):577-87. PubMed ID: 24687919
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
    Gruber A; Carlsson S; Kotzé HF; Marzec U; Sarich TC; Hanson SR
    Thromb Res; 2007; 119(1):121-7. PubMed ID: 16448687
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Outcomes Following Three-Factor Inactive Prothrombin Complex Concentrate Versus Recombinant Activated Factor VII Administration During Cardiac Surgery.
    Harper PC; Smith MM; Brinkman NJ; Passe MA; Schroeder DR; Said SM; Nuttall GA; Oliver WC; Barbara DW
    J Cardiothorac Vasc Anesth; 2018 Feb; 32(1):151-157. PubMed ID: 29217234
    [TBL] [Abstract][Full Text] [Related]  

  • 70. aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
    Kim CH; Simmons SC; Bui CM; Jiang N; Pham HP
    Vox Sang; 2019 Jan; 114(1):63-72. PubMed ID: 30499154
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans.
    Schut AM; Hyseni A; Adelmeijer J; Meijers JC; De Groot PG; Lisman T
    Thromb Haemost; 2014 Aug; 112(2):304-10. PubMed ID: 24695949
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.
    Desmurs-Clavel H; Huchon C; Chatard B; Negrier C; Dargaud Y
    Thromb Res; 2009 Mar; 123(5):796-8. PubMed ID: 18771795
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
    Ragni MV
    Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of Low Dose Recombinant Factor VIIa and 4-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Cardiac Surgery.
    Caldwell L; Bhakta R; Naik N; Knowles BD; Parker J; Van Berkel Patel M
    J Pharm Pract; 2024 Oct; 37(5):1149-1156. PubMed ID: 38261533
    [No Abstract]   [Full Text] [Related]  

  • 75. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
    Martinowitz U; Livnat T; Zivelin A; Kenet G
    Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
    Schneiderman J; Nugent DJ; Young G
    Haemophilia; 2004 Jul; 10(4):347-51. PubMed ID: 15230948
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
    Hillarp A; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Lindahl TL
    J Thromb Haemost; 2011 Jan; 9(1):133-9. PubMed ID: 20946166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.